137 related articles for article (PubMed ID: 10894120)
21. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
[TBL] [Abstract][Full Text] [Related]
22. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
Hirst SJ; Ferger B
Synapse; 2008 Feb; 62(2):85-90. PubMed ID: 17992685
[TBL] [Abstract][Full Text] [Related]
23. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
24. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice.
Selley ML
Brain Res; 2005 Mar; 1037(1-2):1-6. PubMed ID: 15777746
[TBL] [Abstract][Full Text] [Related]
26. Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.
Navneet AK; Appukuttan TA; Pandey M; Mohanakumar KP
Amino Acids; 2008 Aug; 35(2):457-61. PubMed ID: 17701098
[TBL] [Abstract][Full Text] [Related]
27. Neonatal exposure to paraquat or MPTP induces permanent changes in striatum dopamine and behavior in adult mice.
Fredriksson A; Fredriksson M; Eriksson P
Toxicol Appl Pharmacol; 1993 Oct; 122(2):258-64. PubMed ID: 8212007
[TBL] [Abstract][Full Text] [Related]
28. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
30. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
33. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
34. Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine.
Sharma A; Kaur P; Kumar V; Gill KD
Cell Mol Biol (Noisy-le-grand); 2007 Apr; 53(1):48-55. PubMed ID: 17519111
[TBL] [Abstract][Full Text] [Related]
35. Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice.
Muroyama A; Inaka M; Matsushima H; Sugino H; Marunaka Y; Mitsumoto Y
Neurosci Res; 2009 Jan; 63(1):72-5. PubMed ID: 18977253
[TBL] [Abstract][Full Text] [Related]
36. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.
Mochizuki H; Hayakawa H; Migita M; Shibata M; Tanaka R; Suzuki A; Shimo-Nakanishi Y; Urabe T; Yamada M; Tamayose K; Shimada T; Miura M; Mizuno Y
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10918-23. PubMed ID: 11535810
[TBL] [Abstract][Full Text] [Related]
37. Cocaine blocks the dopamine depletion induced by MPTP.
Mayer RA; Jarvis MF; Wagner GC
Res Commun Chem Pathol Pharmacol; 1985 Jul; 49(1):145-8. PubMed ID: 3875884
[TBL] [Abstract][Full Text] [Related]
38. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice.
Cosi C; Colpaert F; Koek W; Degryse A; Marien M
Brain Res; 1996 Aug; 729(2):264-9. PubMed ID: 8876997
[TBL] [Abstract][Full Text] [Related]
39. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
[TBL] [Abstract][Full Text] [Related]
40. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
